0078-1154 : Tafinlar 10 mg Oral Tablet, for Suspension


NDC: 0078-1154
Labeler: Novartis Pharmaceuticals Corporation
Product Type: Human Prescription Drug
Drug Name:  Tafinlar
Dosage Form: Oral Tablet, for Suspension
Application #: NDA217514
Rev. Date: 


NDC Package Codes:

  • 0078-1154-21: 210 TABLET, FOR SUSPENSION IN 1 BOTTLE (0078‑1154‑21)

Active Ingredients:

  • Dabrafenib Mesylate

Dosage Strength:

  • 10 mg

Pharmaceutical Classes:

  • Breast Cancer Resistance Protein Inhibitors [MoA]
  • Cytochrome P450 2B6 Inducers [MoA]
  • Cytochrome P450 2C19 Inducers [MoA]
  • Cytochrome P450 2C8 Inducers [MoA]
  • Cytochrome P450 2C9 Inducers [MoA]
  • Cytochrome P450 3A4 Inducers [MoA]
  • Kinase Inhibitor [EPC]
  • Organic Anion Transporter 1 Inhibitors [MoA]
  • Organic Anion Transporter 3 Inhibitors [MoA]
  • Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]
  • Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]
  • Protein Kinase Inhibitors [MoA]

Related Products:

Based on records with the same trade name.
  • 0078-0681 Tafinlar 75 mg Oral Capsule by Novartis Pharmaceuticals Corporation
  • 0078-0682 Tafinlar 50 mg Oral Capsule by Novartis Pharmaceuticals Corporation
  • 0173-0846 Tafinlar 50 mg Oral Capsule by Glaxosmithkline LLC
  • 0173-0847 Tafinlar 75 mg Oral Capsule by Glaxosmithkline LLC
  • 53873-023 Dabrafenib Mesylate by Glaxosmithkline Inc
  • 53873-024 Dabrafenib Mesylate by Glaxosmithkline Inc

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 0078-1154 QR Code

< Prev: 0078-1112Next: 0078-1161 >




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.